INCY - FDA broadens EUA for Lilly Incyte's baricitinib for COVID-19

The FDA has broadened the Emergency Use Authorization ("EUA") for Eli Lilly (LLY +0.3%) and Incyte's (INCY +0.5%) Olumiant (barictinib) to allow with or without use with Gilead's (GILD -0.2%) Veklury (remdesivir). Before, baricitinib could only be used in combination with remdesivir. The EUA is for hospitalized adults and children two and older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation. The FDA approved the original EUA for baricitinib, which is approved as a rheumatoid arthritis treatment, back in November.

For further details see:

FDA broadens EUA for Lilly, Incyte's baricitinib for COVID-19